Special equipment for GMP production line of anti-hypertensive raw materials Telmisartan raw material filtration washing and drying machine

Telmisartan (Telmisartan), also known as BIBR277, is an angiotensin II-AT1 receptor antagonist developed by Boehringer Inglheim, Germany, and is a new class of antihypertensive drugs. Angiotensin II is formed by angiotensin I through the reaction catalyzed by angiotensin-converting enzyme. It is the main pressurizing factor in the renin-angiotensin system. Its effects mainly include causing vasoconstriction and stimulating the synthesis and release of aldosterone , myocardial excitation and renal tubular sodium reabsorption. The mechanism of action of telmisartan is that it can highly selectively block the combination of angiotensin II and AT1 receptors in many tissues, thereby blocking the vasoconstriction and aldosterone secretion caused by angiotensin II, and achieving Lower blood pressure and protect organs.

Compared with traditional angiotensin-converting enzyme inhibitor (ACE I) antihypertensive drugs, telmisartan has better antihypertensive effect, and because it does not affect angiotensin-converting enzyme (ACE) activity, it does not It will affect the metabolism of ACE to bradykinin and other biologically active substances, and less cause side effects such as dry cough, urticaria and angioedema. In addition, like ACE I antihypertensive drugs, telmisartan has a certain effect on the protection of the heart and renal arteries and the prevention of myocardial infarction. Telmisartan was approved for marketing in the United States in 1998. It has two dosage forms of 40 mg and 80 mg. It is used to treat essential hypertension. It is a new AT antagonist with long-acting, high-efficiency and low toxicity. It has a long half-life and can be used once a day. It is currently a better sartan drug, and it is suitable for all types of hypertensive patients who cannot tolerate or are allergic to other antihypertensive drugs

But the traditional route of producing this medicine has low yield and complex operation, which is not conducive to cost reduction, and three wastes pollution occurs, which causes greater pollution to the environment.

Wuxi ZhangHua Machinery Co., Ltd. has carried out a lot of design and development work, and finally successfully developed the SR-tubular-cone reaction filtration and drying multifunctional machine, the invention patent number: ZL2017 2 1560677.6. It has realized a major breakthrough in the filtration, washing and drying equipment of telmisartan raw materials. Breakthrough, and reached a strategic partnership with well-known pharmaceutical companies, making outstanding contributions to the quality of anti-hypertensive raw material medicine equipment.

Features and advantages of telmisartan raw material filtration washing and drying machine

1. Reduce the chance of contamination and help ensure the sterility of the product

Putting multiple processes such as washing, filtering, and drying in one airtight device to complete multiple operations reduces the risk of pollution transferred between different devices. Protective gases such as N2 can also be passed through the device to isolate contact with the external environment, greatly improving The probability of product contamination is reduced, which is conducive to the guarantee of product sterility.

2. Online CIP and SIP can be realized, which is convenient for cleaning and sterilization or cleaning and sterilization after disassembly

The telmisartan raw material filtration, washing and drying all-in-one machine developed and produced by ZhangHua Machinery has changed the disadvantages of centrifugation, filtration or oven that are not suitable for online cleaning and sterilization; by installing spray balls, connecting pure steam, etc., adding cleaning solvents when necessary , which can automatically complete the cleaning and sterilization functions without disassembling the equipment, providing equipment guarantee for aseptic production.

3. Pollution-free sampling can be realized

The special filtering, washing and drying equipment for telmisartan raw materials is designed with a safe and non-polluting sampling valve device. When sampling, it is not necessary to open the equipment cover or cabinet door, which avoids the contamination of drugs by impurities brought in by sampling tools.

4. Improve production efficiency and save operating costs

(1) Since the work completed by multiple equipment operations in multiple processes is completed by one equipment, the operation time is reduced and the production cycle is shortened;

(2) The site saves the space occupied by the clean area and reduces construction costs;

(3) It also saves operating costs such as air conditioning and refrigeration, which has certain effects on reducing costs, increasing efficiency, and saving energy.

5. Save labor costs, but also conducive to stable product quality

The production process is reduced, the degree of automation is improved, the labor force is reduced, and the error and the probability of contamination in the operation of the staff are also reduced, which is conducive to the uniform and stable quality of medicines between batches.

6. In line with the development trend of cleaner production in the world

The fully enclosed production process in pharmaceutical production has always been the best production method pursued by pharmaceutical manufacturers. In this way, the pharmaceutical production process is not affected by external or artificial impurities, pollution, etc., and the quality of pharmaceuticals can be guaranteed most effectively, and Production also has minimal environmental impact. This production method is in line with the development trend of cleaner production in the world.

There are a large number of patients with hypertension in my country, and the market for antihypertensive drugs is very large.

Although calcium antagonists and ACEI are still dominant at present, from domestic and foreign perspectives, the prospect of sartans is generally optimistic. The sales momentum of sartan antihypertensive new drugs has been on the rise since the advent. According to the forecast of Datamonitor, the sales of losartan potassium will reach 1.68 billion US dollars in 2005, and the sales of the whole sartan class will be 3 billion US dollars, 21 At the beginning of the century, the antihypertensive drug market will be dominated by ARB. Telmisartan has a long half-life and is a real once-a-day antihypertensive drug with a sustained and stable antihypertensive effect. It can be called the best sartan drug at present.

Therefore, the development of telmisartan has broad market prospects. Wuxi ZhangHua Machinery sincerely looks forward to cooperating with pharmaceutical companies to continuously improve the quality of the telmisartan raw material filtering, washing and drying machine. Choose ZhangHua! Choose confidence!